RxDoctor Payments Data

Alain Litwin

Addiction Medicine · Bronx, NYNPI 1366527368

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (50.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Gilead accounts for 89.6% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $66,291, 4.9 times the $13,600 reported in 2019. Among addiction medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$123,714in general payments, 2019–2025

Across 145 payments — averaging $853.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$111K
  • Merck$13K
  • Siemens Medical Solutions USA, Inc.$130
  • AbbVie$58
  • Alkermes, Inc.$26
$1,644,534in research payments, 2019–2025

Across 288 payments — averaging $5710.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Indivior Inc.$1M
  • Gilead$628K

What the payments were for

  • Consulting fees$45,01736%
  • Speaking & faculty fees$62,67951%
  • Travel & lodging$12,70010%
  • Food & beverage$3,3053%
  • Education$130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead138$110,849
Merck2$12,650
Siemens Medical Solutions USA, Inc.1$130
AbbVie2$58
Alkermes, Inc.2$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$123,714 in reported general payments places this provider in the 95th percentile of 125 addiction medicine providers in New York.

See all addiction medicine providers in New York →

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl32$2,725

Paid to pharmacies, not to this prescriber.

Other addiction medicine in Bronx

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →